Condition: Autism Spectrum Disorder (ASD) · Sponsor: Shanghai Auzone Biological Technology Co., Ltd.
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
This description comes directly from the study's public registry record.
Xiaolong Hou · +86-21-65039008 · houxl@auzonebio.com
Always discuss trial participation with your own doctor first.
| Peking University Sixth Hospital | Beijing, China | Recruiting |
| The Second Xiangya Hospital of Central South University | Changsha, China | Not Yet Recruiting |
| West China Hospital of Sichuan University | Chengdu, China | Not Yet Recruiting |
| Nanjing Brain Hospital, The Affiliated Brain Hospital of Nanjing Medical University | Nanjing, China | Not Yet Recruiting |
| Tianjin Mental Health Center | Tianjin, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06757504